Marcus is Managing Partner of Quadrant Private Equity [QPE], which he joined in March 2006 from his role as joint Head of Private Equity at AMP.
Marcus has worked in the private equity industry for over 24 years. He commenced his career in private equity in the UK with NatWest Ventures, before joining AMP in 1994. Here he developed AMP’s private equity activity over a 12 year period. During this time Marcus worked on over 15 completed transactions. The key deals he led include Tasman Building Products, Olex Cables, Vision Group and Orphan Australia.
Marcus is a member of all QPE fund Investment Committees and a Director of Quadrant investee companies: Icon, Super A-Mart/Barbeques Galore and Home Care Holdings. He was previously Chairman of Virtus Health and is currently Chair of the Icon Acquisition Sub-committee. Marcus holds a degree in Mathematics and a Masters of Business Administration.
Eric brings a wealth of business acumen to the board, with an extensive background in the finance and health sectors. In his role as Managing Director and CEO of leading health insurer, Bupa Australia Group, Eric drove significant financial growth and led the merger of MBF and Bupa in 2008.
Since stepping down from that role, Eric has pursued a full-time career as a Non-Executive Director. In addition to sitting on the Icon Group board, he is Chairman of First American Title Insurance and a Non-Executive Director of Credit Corp Group. He was previously chairman of SFG Australia and Firstfolio Ltd, and a Non-Executive Director of Healthscope Limited. Eric was also the Chairman of Odyssey House and Non-Executive Director of Clean Up Australia and Clean Up the World.
Prior to joining MBF in 2002, Eric was the Managing Director of NRMA Insurance Limited and Chief Executive Officer of NRMA Limited. In 2000, he led the demutualisation of NRMA and the listing of Insurance Australia Group (NRMA Insurance Group Limited) on the ASX.
Eric has a Bachelor of Economics with statistics and accounting majors. He is a Fellow of the Australian Institute of Company Directors and a Fellow of the Institute of Chartered Accountants and was previously president of the Insurance Council of Australia (ICA).
Non-Executive Director, Founding Chairman and Chairman – Icon Asia
Stuart Giles was the Founding Chairman and driving force behind the establishment of Icon Cancer Care. He remains a significant investor in the Icon Group and plays an active role at a Board level, with a strong focus on driving international growth. His role as Chairman of Icon Asia encompasses leading the Group’s development throughout South-East Asia, including Icon SOC [Singapore Oncology Consultants] and the joint venture with China-based healthcare group Yibai.
Anyone who has met Stuart knows he brings an energetic and innovative approach to developing commercial success and expanding the boundaries of healthcare. He’s been publicly recognised for his commercial expertise in forums including the 2010 Ernst and Young Entrepreneur of the Year where he was named a Regional Winner and National Finalist.
A pharmacist by background, Stuart and his wife, Cathie Reid, own and operate a number of pharmacies around Australia, to which Icon Group provides management services.
Stuart is passionate about contributing to the community and served on the Board of Directors for the AEIOU Foundation for Children with Autism. He supported medical research as a Founding Platinum sponsor of the Gallipoli Research Foundation, before he and Cathie launched the Epic Good Foundation in 2015.
Dr Ian Irving
Dr Ian Irving brings strong leadership to the board having performed senior clinical and administrative roles in the cancer care sector and is currently Medical Director of Icon Cancer Care. Ian spent several years in haematology practice at Icon Townsville, and during that time was also the Director of Haematology and Bone Marrow Transplantation at the Townsville Hospital and the Clinical Director of the Institute of Cancer from 2006 – 2013. He was also responsible for consolidating and expanding tertiary level cancer care in North Queensland. He continues his practice at Icon Cancer Care Wesley.
Further to his broad haematological knowledge, Ian has a special clinical interest in lymphoma, myelodysplasia and myeloproliferative disorders. He has sat on national and international committees and advisory boards, focusing on haematological disorders such as chronic myeloid leukaemia, myelofibrosis, myelodysplasia, lymphoma and bone marrow transplantation. Ian is a strong advocate for clinical trial research, participating in phase I, II and III multi-centre clinical trials.
The minute you meet Mark you know he is passionate about access to world-class healthcare. As the Group CEO, and a highly-regarded radiation therapist, Mark knows all too well the impact of cancer on patients, family and society. His leadership style is simple, nurture and challenge a team to deliver exceptional cancer care and grow the business to deliver that care for as many people as possible.
Since taking the reins in 2015, Mark has delivered a robust growth profile. In this time the Group has expanded into China and Singapore, with a significant South-East Asia reach, delivered a 50% increase in their radiation oncology footprint and driven acquisition in the chemotherapy compounding space to deliver one of Australia’s largest oncology manufacturers. Before this Mark led the Radiation Oncology Centres [ROC] team, including the successful acquisition of ROI and Oceania into the radiation oncology business.
Mark was a State Finalist for the Australian Institute of Management [AIM] Queensland Manager of the Year in 2014 and regional winner of the AIM Excellence Award 2015. He has a Master of Business Administration from Deakin University and is a Fellow of both the AIM and the Australian Institute of Radiography [AIR].
Simon is an Investment Director with Quadrant Private Equity. He joined Quadrant in 2008 from Melbourne-based mid-market private equity fund, Advent Private Capital.
Prior to this, Simon worked for Credit Agricole Indosuez Private Equity in London, investing in mid-market private equity and mezzanine opportunities. Simon began his career with Barclays Capital in fixed income research and trading, latterly working in the European High Yield Group.
Simon is a Director of Quadrant investee company, Icon. Simon holds a degree in Geography, a Masters of Business Administration and is a member of the Australian Institute of Company Directors.
Prof Jonathan Ramsay
As a Founding Partner of ROQ [now ROC] and highly regarded Radiation Oncologist, Jonathan brings a wealth of knowledge to his position on the board.
Driven by a passion for regional cancer care, Jonathan oversaw the development of ROQ from a single centre in Toowoomba to centres in Cairns, Gold Coast and Springfield, and the eventual acquisition of ROI and Oceania to become ROC.
Jonathan continues to run an accomplished clinical practice. In 2000 he was involved in the start-up of Peplin Biotechnology, which developed successful topical treatments for skin cancers. He practices at Mater Hospital South Brisbane, where he has since 1994 and also consults at ROC Greenslopes and Redland.
From the moment you meet David you know his integrity runs through every part of the Slade business. As CEO, his dedication to customers, commitment to patient care and vision has seen the company become a leading national provider of hospital and compounding pharmacy services.
His deep understanding of the healthcare industry not only underpins the 50 year old Slade Pharmacy business, but has been integral to the evolution of Slade Health. Seeing an opportunity to evolve outside of pharmacy, David established Slade Health in 2012. He recently led the acquisition of Fresenius Kabi and McBeath Oncology Compounding, which makes Slade Health one of Australia’s largest chemotherapy compounders.
David is passionate about innovation and using technology to improve the operations of the business. He was the first in Australia to introduce robotic dispensing technology into hospital pharmacy, develop and deploy an online ordering system for chemotherapy and unique barcoding technology to support patient safety in hospitals.
As the driving force behind Epic Group, including Epic Pharmacy and Epic Good Foundation, Cathie brings a passion for innovation to her role as Digital Advisor to the Board. As a significant contributor to Icon Group’s evolution and the depth of the business, Cathie intimately understands the operational challenges and opportunities facing the Group.
A tech geek at heart, Cathie has always believed in the role digital solutions have to play in the delivery of exceptional healthcare. It is this commitment that saw her found Epic Digital, a business focused on technology solutions that connect healthcare professionals with their patients, improving access to information, facilitating work flows and empowering patients to actively manage their health. Now part of Icon Group, Epic Digital is bridging the gap between the paper-based industry we know today and the digital future of tomorrow.
Cathie currently sits as on the Board of Assured Digital Group as a Director, the United Kingdom’s leading provider of digital infrastructure and information governance for sovereign data assets, and is the Chair of Flamingo Customer Experience Inc., an innovative software-as-a-service (SaaS) company developing customer experience automation platforms designed for selling complex financial products online. She has been recipient of several industry awards and honours including: induction into the Australian Businesswomen’s Hall of Fame in 2015, named one of the Top 100 Women of Influence by the Australian Financial Review in 2013, winner of the National Telstra Business Women’s Award in 2011, and recognised by Monash University with a Distinguished Alumni Award for Professional Achievement in 2012.
Cathie’s fascination in breaking new ground saw her invited to be part of the original Google Glass Explorer program and is one of Virgin Galactic’s future astronauts. She eagerly awaits the opportunity to travel into space and see the world from a very different perspective.